Type 2 & other diabetes

Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial

J Clin Endocrinol MetabPublished Secondary analysis of the T4DM randomised controlled trial

Authors' conclusion

In this diabetes prevention trial, weight loss induced by a lifestyle intervention improved HR-QOL and psychosocial function in more domains than testosterone treatment. The magnitude of weight and waist circumference reduction were predicted by baseline physical function, depressive symptomology, and sense of coherence.

Study context

Population
Men ≥50 years at high risk for T2D, without pathologic hypogonadism, 6 Australian centers648 with complete data
Participants
1,007 men
Comparison
Testosterone undecanoate vs placebo on background lifestyle program
Primary endpoint
Self-reported measures of HR-QOL/psychosocial function
Follow-up
2 years
Methodological detailsplacebo-controlled, multicentre, 2-year
  • Placebo-controlled
  • Multicentre
  • 2-year

Primary result

As reported in the abstract

HR-QOL/psychosocial function · 24 months
  • Most measures not different between treatment arms
  • Testosterone vs placebo improved subjective social status and sense of coherence

Further findings

Baseline health-related quality of life (HR-QOL)/psychosocial function as predictor of testosterone effect on glycemic outcomes

Baseline measures did not predict effect of testosterone on glycemic outcomes (T4DM primary endpoints)

Weight loss and HR-QOL/psychosocial function, irrespective of allocation

Larger weight decreases associated with improved mental quality of life, mastery and subjective social status

Baseline predictors of weight loss

Better baseline physical function, greater sense of coherence and fewer depressive symptoms associated with greater weight decreases; similar for waist circumference

Original publication

Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial. J Clin Endocrinol Metab. Published 9 February 2024. doi:10.1210/clinem/dgae085

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.